Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation (scientific article published on 20 January 2016)

Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor

Q24646341

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Q25938999

The two-state model of receptor activation

Q28288075

The adenosine a2b receptor: its role in inflammation

Q28303755

Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists

Q28343629

Adenosine A2B receptor blockade slows growth of bladder and breast tumors

Q30416420

Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells

Q32065053

Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias

Q33748133

Hypoxia, clonal selection, and the role of HIF-1 in tumor progression

Q33924693

Adenosine and cardioprotection during ischaemia and reperfusion--an overview

Q34058386

Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective

Q34279918

Mechanisms of inverse agonism at G-protein-coupled receptors

Q34519411

A2B adenosine receptor blockade inhibits growth of prostate cancer cells.

Q34546999

Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors

Q34968199

The use of constitutively active GPCRs in drug discovery and functional genomics

Q34981350

The hypoxic tumour microenvironment and metastatic progression

Q35125467

Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.

Q35454522

Adenosine A2b receptor promotes progression of human oral cancer

Q35728866

Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery

Q36365614

Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant?

Q36729774

Host A(2B) adenosine receptors promote carcinoma growth

Q36840284

Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.

Q37448109

Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease

Q37599075

Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury.

Q37625454

HIF-dependent induction of adenosine A2B receptor in hypoxia

Q38308002

Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues.

Q38907149

Pharmacology and structure of isolated conformations of the adenosine A₂A receptor define ligand efficacy

Q39190700

Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells

Q39682195

Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins

Q40784172

Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors

Q40858867

Influence of receptor number on the cAMP response to forskolin in Chinese hamster ovary cells transfected with human beta2-adrenoceptor

Q42456574

1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.

Q45944058

Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.

Q51797215

Improving Potency, Selectivity, and Water Solubility of Adenosine A1 Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3-cd]purinediones

Q57708485

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

prostate cancer

Q181257

P304

page(s)

36-44

P577

publication date

2016-01-20

P1433

published in

Journal of Pharmacology and Experimental Therapeutics

Q1500272

P1476

title

Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation

P478

volume

357

Reverse relations

cites work (P2860)

Q28074665	Adenosine A2B Receptor: From Cell Biology to Human Diseases
Q39148961	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.
Q94464383	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Q51451305	Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy.
Q57292376	Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
Q91950939	Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future
Q48337573	Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain
Q39341570	Role of the Second Extracellular Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity.
Q37642476	Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice.
Q60921609	Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
Q46140918	Targeting immunosuppressive adenosine in cancer
Q49787788	The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma.
Q64994757	Tritium-labeled agonists as tools for studying adenosine A2B receptors.
Q87944215	[B cells in head and neck oncology]